Cook Medical receives CE Mark for new thumbwheel deployment system for Zilver PTX drug-eluting peripheral stent

CE Mark has been awarded to the new rotating thumbwheel deployment system for Cook Medical’s Zilver® PTX® drug-eluting peripheral stent. The new system, which is now available for purchase in the UK, Ireland, Germany, Spain and Italy, provides simple deployment for the world’s first and only approved drug-eluting stent for the superficial femoral artery (SFA).

“Our objective when designing the new handle was to improve accuracy and deliverability on the previous pin-and-pull system,” said Lindsay Koren, global product manager for stent development. “We have not only succeeded in our engineering and production goals, but have surpassed many of our expectations for several of the new features.”

The thumbwheel design features include an ergonomic handle that facilitates single-handed deployment. In addition to the new deployment system, 120 mm length Zilver PTX stents are also now available while all lengths on the new delivery system are now CE marked with a 24-month shelf life.

Dr. Andrew Holden, director of Interventional Services at Auckland City Hospital and associate professor of Radiology at Auckland University School of Medicine in New Zealand, is the first physician in the world to use the new deployment system in his practice.

“Based on my own experience, I’ve found that Cook’s new Zilver PTX deployment system has overcome the challenges associated with the previous system,” he said. “The new thumbwheel system allows for greater control and accuracy making it significantly easier for me to deploy the Zilver PTX stent.”

Watch a video of Dr. Holden using the new delivery system to place a Zilver PTX here: http://bit.ly/1F7xukT.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Polymer drug-eluting and polymer-free drug-coated stents safe and effective for patients with high bleeding risk